ATE260338T1 - Hefestämme und modifizierte albumine - Google Patents

Hefestämme und modifizierte albumine

Info

Publication number
ATE260338T1
ATE260338T1 AT95909880T AT95909880T ATE260338T1 AT E260338 T1 ATE260338 T1 AT E260338T1 AT 95909880 T AT95909880 T AT 95909880T AT 95909880 T AT95909880 T AT 95909880T AT E260338 T1 ATE260338 T1 AT E260338T1
Authority
AT
Austria
Prior art keywords
pct
albumin
yeast strains
yeast
yap3p
Prior art date
Application number
AT95909880T
Other languages
English (en)
Inventor
Sean Martin Kerry-Williams
Sarah Catherine Gilbert
Original Assignee
Delta Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Biotechnology Ltd filed Critical Delta Biotechnology Ltd
Application granted granted Critical
Publication of ATE260338T1 publication Critical patent/ATE260338T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95909880T 1994-03-05 1995-03-01 Hefestämme und modifizierte albumine ATE260338T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9404270A GB9404270D0 (en) 1994-03-05 1994-03-05 Yeast strains and modified albumins
PCT/GB1995/000434 WO1995023857A1 (en) 1994-03-05 1995-03-01 Yeast strains and modified albumins

Publications (1)

Publication Number Publication Date
ATE260338T1 true ATE260338T1 (de) 2004-03-15

Family

ID=10751353

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95909880T ATE260338T1 (de) 1994-03-05 1995-03-01 Hefestämme und modifizierte albumine

Country Status (13)

Country Link
US (1) US5965386A (de)
EP (1) EP0749478B1 (de)
JP (1) JP3795073B2 (de)
KR (1) KR100372514B1 (de)
AT (1) ATE260338T1 (de)
AU (1) AU683728B2 (de)
CA (1) CA2183241C (de)
DE (1) DE69532603T2 (de)
DK (1) DK0749478T3 (de)
ES (1) ES2216007T3 (de)
GB (2) GB9404270D0 (de)
PT (1) PT749478E (de)
WO (1) WO1995023857A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6110703A (en) * 1996-07-05 2000-08-29 Novo Nordisk A/S Method for the production of polypeptides
EP0909312B1 (de) * 1996-07-05 2002-12-04 Novo Nordisk A/S Verfahren zur produktion von polypeptiden
WO1998001473A1 (en) * 1996-07-05 1998-01-15 Novo Nordisk A/S Method for the production of precursors of insulin, precursors of insulin analogues, and insulin like peptides
US6274305B1 (en) 1996-12-19 2001-08-14 Tufts University Inhibiting proliferation of cancer cells
US6265186B1 (en) 1997-04-11 2001-07-24 Dsm N.V. Yeast cells comprising at least two copies of a desired gene integrated into the chromosomal genome at more than one non-ribosomal RNA encoding domain, particularly with Kluyveromyces
WO1999037758A2 (en) * 1998-01-27 1999-07-29 The Board Of Regents Of The University And Community College System Of Nevada On Behalf Of The University Of Nevada-Reno Expression of proteolytically-sensitive peptides
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
WO2002022685A2 (en) * 2000-09-11 2002-03-21 Kufe Donald W Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
WO2002058450A2 (en) * 2000-12-22 2002-08-01 Dana-Faber Cancer Institute, Inc. Regulation of cell growth by muc1
US7507413B2 (en) * 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
JP2003047471A (ja) * 2001-08-01 2003-02-18 Kirin Brewery Co Ltd 異種タンパク質の分泌生産に優れた改変酵母およびその酵母を用いた異種タンパク質の製造法
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US20060122374A1 (en) 2002-02-07 2006-06-08 Peter Mertins Albumin-fused anti-angiogenesis peptides
US7879365B2 (en) * 2002-02-07 2011-02-01 The Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of dermal and mucosal irritation
JP4464269B2 (ja) * 2002-04-26 2010-05-19 協和発酵キリン株式会社 哺乳類型糖鎖生産メチロトロフ酵母
EP1534835B1 (de) * 2002-06-29 2010-09-08 Korea Research Institute of Bioscience and Biotechnology Yapsin-mangelmutantenstamm von hansenula polymorpha sowie verfahren zur herstellung rekombinanter proteine damit
US20080090770A1 (en) * 2003-04-11 2008-04-17 Belmares Michael P Modulation of Muc1 Mediated Signal Transduction
WO2005042573A1 (en) * 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
US9057061B2 (en) 2003-12-23 2015-06-16 Novozymes Biopharma Dk A/S Gene expression technique
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
RU2006128593A (ru) * 2004-01-07 2008-02-20 Тримерис, Инк. (Us) Синтетические пептиды, производные области hr2 белка gp41 вич, и их применение в терапии для ингибирования проникновения вируса иммунодефицита человека
EP1718367A1 (de) * 2004-02-23 2006-11-08 Genzyme Corporation Muc1-antagonisten-verstärkung von durch todes-rezeptor-ligand ausgelöster apoptose
WO2006034455A2 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
EP2330200B1 (de) 2004-12-23 2017-04-05 Albumedix A/S Genexpressionstechnik
KR20080074120A (ko) 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
ATE537183T1 (de) 2006-02-02 2011-12-15 Trimeris Inc Hiv-fusionshemmerpeptide mit verbesserten biologischen eigenschaften
DK2046826T3 (da) 2006-07-24 2011-10-24 Biorexis Pharmaceutical Corp Exendin-fusionsproteiner
WO2008019368A2 (en) * 2006-08-07 2008-02-14 Teva Biopharmaceuticals Usa, Inc. Albumin-insulin fusion proteins
KR20090060294A (ko) 2006-09-08 2009-06-11 암브룩스, 인코포레이티드 변형된 인간 혈장 폴리펩티드 또는 Ｆｃ 스캐폴드 및 그의 용도
WO2008097844A2 (en) * 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
WO2008097840A2 (en) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
CN101678125A (zh) * 2007-04-03 2010-03-24 特里梅里斯公司 用于递送抗病毒肽治疗剂的新制剂
EP2594583A1 (de) 2007-08-08 2013-05-22 Novozymes Biopharma DK A/S Transferrinvarianten und Konjugate
CA2700354A1 (en) * 2007-09-25 2009-04-02 Trimeris, Inc. Novel methods of synthesis for therapeutic antiviral peptides
US20110294988A1 (en) 2009-02-06 2011-12-01 Novozymes Bio Pharma DK A/S Purification Process
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
AU2010311332B2 (en) 2009-10-30 2015-04-23 Albumedix Ltd. Albumin variants
EP2504355B1 (de) 2009-11-25 2015-07-22 Novo Nordisk A/S Verfahren zur herstellung von polypeptiden
WO2011103076A1 (en) 2010-02-16 2011-08-25 Medlmmune, Llc Hsa-related compositions and methods of use
CN102812119B (zh) * 2010-03-26 2015-05-20 朝日集团控股株式会社 酵母培养方法
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
EP2675471A4 (de) * 2011-02-15 2015-01-28 Medimmune Llc Mit hsa zusammenhängende zusammensetzungen und verwendungsverfahren
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
AU2012222833B2 (en) 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
WO2012150319A1 (en) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
EP3330283A3 (de) 2012-03-16 2018-07-11 Albumedix A/S Albuminvarianten
IN2015DN01115A (de) 2012-07-13 2015-06-26 Zymeworks Inc
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
WO2014138371A1 (en) 2013-03-06 2014-09-12 Glaxosmithkline Llc Host cells and methods of use
US20160152686A1 (en) 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
EP3027752B1 (de) * 2013-07-01 2018-08-08 Biocon Limited Signalsequenz für proteinexpression in pichia pastoris
BR112018003179A2 (pt) 2015-08-20 2018-09-25 Albumedix As conjugados e variantes de albumina
WO2020092448A1 (en) 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
US12629445B2 (en) 2020-03-20 2026-05-19 Bard Peripheral Vascular, Inc. Reactive hydrogel forming formulations and related methods, including methods of preparation
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
WO2022146917A1 (en) 2020-12-28 2022-07-07 Davol Inc. Reactive dry powdered hemostatic materials comprising a protein and a multifunctionalized modified polyethylene glycol based crosslinking agent
CN114957448B (zh) * 2022-06-08 2023-08-25 中国农业科学院生物技术研究所 一种高效表达α-乳白蛋白的酵母菌株和α-乳白蛋白及其应用
CN118580980B (zh) * 2024-08-07 2024-10-15 通化安睿特生物制药股份有限公司 一种用于制备重组人白蛋白的重组工程菌及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01240191A (ja) * 1988-02-16 1989-09-25 Green Cross Corp:The 酵母で機能する新規シグナルペプチドおよびこれを用いた異種蛋白質の分泌発現
ATE157703T1 (de) * 1991-12-16 1997-09-15 Ciba Geigy Ag Endoplasmatisches retikulum-ständige rekombinante dibasische endoprotease und deren verwendungen
US5440018A (en) * 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same

Also Published As

Publication number Publication date
DK0749478T3 (da) 2004-06-28
AU1818395A (en) 1995-09-18
CA2183241C (en) 2002-05-21
GB2301365B (en) 1997-07-30
GB9616724D0 (en) 1996-09-25
GB9404270D0 (en) 1994-04-20
GB2301365A (en) 1996-12-04
EP0749478B1 (de) 2004-02-25
DE69532603T2 (de) 2005-01-05
EP0749478A1 (de) 1996-12-27
WO1995023857A1 (en) 1995-09-08
DE69532603D1 (de) 2004-04-01
CA2183241A1 (en) 1995-09-08
US5965386A (en) 1999-10-12
PT749478E (pt) 2004-07-30
JPH09509581A (ja) 1997-09-30
ES2216007T3 (es) 2004-10-16
KR100372514B1 (ko) 2004-04-30
AU683728B2 (en) 1997-11-20
JP3795073B2 (ja) 2006-07-12

Similar Documents

Publication Publication Date Title
DE69532603D1 (de) Hefestämme und modifizierte albumine
GB2302329B (en) Yeast strains
WO1996017924A3 (en) Novel hedgehog-derived polypeptides
ZA953629B (en) Soluble polypeptidic fragments of lag-3 protein method of production thereof therapeutic composition anti-idiotype antibodies
ES2072918T3 (es) Mejoras en la produccion de polipeptidos.
DE69435049D1 (de) Chimäre proteine zur vermeidung der komplementaktivierung
ATE112687T1 (de) Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen.
DE69333951D1 (de) Rekombinantes pseudomonas exotoxin mit gesteigerter aktivität
ATE121781T1 (de) Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions- kassetten, transformierte hefen und verfahren zur herstellung dieser proteine.
ATE106943T1 (de) Variante cd44-oberflächenproteine, diese kodierende dna-sequenzen, antikörper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie.
PT758241E (pt) Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses
DE69230135D1 (de) Dna-sequenz, die für rinder-g(a)-lactalbumin kodiert, und nutzungsmethoden
DE69431601D1 (de) Neue verwendung von dexmedetomidin
BG103016A (en) Polypeptides capable of forming antigen-binding structures of specificity to rhesus d antigens, their encoding dna and method for their prparation and application
ATE233314T1 (de) Eine sekretionssequenz für die herstellung von heterologen proteinen in hefe
ATE360695T1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
ES2139014T3 (es) Metodo para la produccion de un hidrolizado de carne y uso del hidrolizado de carne.
GR3030011T3 (en) Protein preparation for the prevention and therapy of periodontitis or other bacterial pathologies of the oral cavity
EP1997510A8 (de) Nicht-neurotoxische Plasminogen Aktivierende Faktoren zur Behandlung von Schlaganfall
DE69030920D1 (de) Verfahren zur herstellung von pai-2
ATE165619T1 (de) Rekombinante antikörper an der oberfläche von e.coli
AU3347293A (en) Expression signal-peptide-free staphylokinases
DE69330246D1 (de) Impfstoffe auf der basis von streptokinase
DE59611353D1 (de) Transketolase-verwandtes protein
DE59407666D1 (de) VERFAHREN ZUR HERSTELLUNG VON 8-g(a),12-OXIDO-13,14,15,16-TETRANORLABDAN

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0749478

Country of ref document: EP

EEFA Change of the company name
EEIH Change in the person of patent owner